• Regeneron outlined 10 oncology and thrombosis abstracts scheduled for ESMO 2026 in Madrid on Oct. 23-27.
• Late-breaking Phase 3 C-POST overall survival update for adjuvant Libtayo in high-risk CSCC will be presented Oct. 25.
• Regeneron expects the longer-term survival readout to reinforce Libtayo’s position as standard of care in this setting.
• Final Phase 2 neoadjuvant Libtayo analysis in resectable stage II-IV CSCC will be presented Oct. 24.
• Factor XI antibodies cenvacibart and amrecibart data will be presented, targeting cancer-associated thrombosis with a potential bleeding-risk advantage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060700PRIMZONEFULLFEED9840120) on October 06, 2026, and is solely responsible for the information contained therein.